|
New Oncology Targets from Fragment Leads |
|
Thursday, September 19, 2024 |
|
10:00 EDT / 15:00 BST / 16:00 CEST |
|
|
|
John Spencer, PhD |
• |
Head of Medicinal Chemistry, Sussex Drug Discovery Center |
|
• |
Scientific Advisory Member (grant committee) Prostate Cancer UK |
|
|
In This Webinar, You Will Learn: |
• |
A novel fragment-based drug discovery |
• |
The development of p53 activators |
• |
The high-throughput exploration of crude reaction mixtures through automated
chemistry and X-ray crystallography |
|
About This Webinar: |
The p53 protein, often referred to as the “guardian of the genome,” plays a critical role in regulating cell cycle, DNA repair, and apoptosis. Mutations or dysregulations in p53 are implicated in over half of all human cancers, making it a prime target for therapeutic intervention. Despite significant progress, developing effective p53 activators poses numerous challenges. As a nuclear transcription factor, p53 does not possess typical drug target features. |
Fragment-Based Drug Discovery (FBDD) is a powerful approach in drug discovery that involves the identification of small chemical fragments binding to a target protein, which are then optimized into potent compounds. We recently developed a streamlined workflow integrating low-cost robotics and analytical techniques to rapidly gather structural data on binding sites (Grosjean et al). By using crystallographic fragment screens of the pleckstrin homology domain interacting protein (PHIP(2)), 1800 compounds were synthesized using an OpenTrons OT-1 liquid handler. The workflow included multi-step reactions, deconvolution of crude reaction mixtures with MScheck, and subsequent X-ray diffraction analysis. This efficient process identified 22 crystallographic hits, with one molecule showing notable binding affinity. This approach promises to significantly expedite the fragment-to-lead drug development process. |
|
|
MCE Webinar |
The MCE webinar is committed to offering an official platform for global experts and researchers in the fields of medicine, pharmacy, biology, and chemistry.
By facilitating knowledge exchange, the MCE webinar aims to contribute to the global biopharmaceutical industry by promoting extensive sharing of information and expertise. |
|
|
|
|
MCE USA |
Tel: 609-228-6898 |
E-mail: sales@MedChemExpress.com |
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA |
MCE Europe |
Tel: +4686500910 |
E-mail: eu.sales@MedChemExpress.com |
Address: Bergkällavägen 37C 192 79 Sollentuna SWEDEN |
MCE China |
Tel: +86-021-58955995 |
E-mail: sales@MedChemExpress.cn |
Address: Building 3,1999 Zhangheng Road, Pudong New District, Shanghai |
|
|
Products are for research use only and are not intended for human use. We do not sell to patients.
|
|
|